Icon opens research lab in China
Irish clinical trials firm Icon has opened a new contract research laboratory in China, marking what analysts said was further evidence of the company's ambitions in the region.
Icon has partnered with Fountain Medical Development to open the lab in Tianjin, close to the capital, Beijing. The facility is Icon's third in the Asia-Pacific region. It already has one in Bangalore, India, and another in Singapore.
Last April, Icon formed an alliance with Chinese contract research firm Tigermed Consulting in order to provide pharmaceutical clients with access to China's clinical trials market.
The new lab in China will offer a range of testing services, including chemistry, haematology, coagulation and immunology. The Tianjin facility will provide support services to clinical investigators throughout China, helping to expedite study completion by cutting the distance between clinical trial sites and existing laboratory testing facilities, according to Icon.
Separately, Icon will be supplying clinical support services to the US National Institute of Allergy and Infectious Diseases in conjunction with a local partner, Technical Resources International. The initial contract is worth $19m (€15.2m) with a potential value of $171m (€137m) over seven years.